The Claim

Orlistat, phentermine/topiramate, and naltrexone/bupropion are associated with an increased risk of serious adverse events in adults with essential hypertension compared to placebo, with risk ratios of 1.45, 0.85, and 1.05 respectively, based on moderate-certainty evidence from randomized controlled trials involving over 10,000 participants; however, the evidence for all adverse events remains uncertain for orlistat and phentermine/topiramate.

Source: Long-term effects of weight-reducing drugs in people with hypertension.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
59score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

In adults with essential hypertension, orlistat increases the risk of serious adverse events compared to placebo, phentermine/topiramate does not increase risk, and naltrexone/bupropion slightly increases risk, based on clinical trial data; however, data on all adverse events for orlistat and phentermine/topiramate is not conclusive.

See the scientific wording

Orlistat, phentermine/topiramate, and naltrexone/bupropion are associated with an increased risk of serious adverse events in adults with essential hypertension compared to placebo, with risk ratios of 1.45, 0.85, and 1.05 respectively, based on moderate-certainty evidence from randomized controlled trials involving over 10,000 participants; however, the evidence for all adverse events remains uncertain for orlistat and phentermine/topiramate.

Why this might work

These drugs increase nervous system activity that raises heart rate and tightens blood vessels, which forces the heart to work harder and can cause damage to organs like the heart, brain, or kidneys in people who already have high blood pressure.

Supported mechanismbased on 1 study

What the research says

1 study
  1. Study: Long-term effects of weight-reducing drugs in people with hypertension.

    The study found that orlistat and naltrexone/bupropion may increase serious side effects in people with high blood pressure, while phentermine/topiramate might not — but we’re not very sure about that one. The numbers in the claim match what the study found.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.